ASCO '12 Abstract Dump: Cancer Stocks in Focus - TheStreet
.....While investors were flooded with
new cancer drug data Wednesday,
ASCO did hold back some of the some important and potentially
stock-moving research for a more high-profile release at the meeting
itself.
Key cancer drug data that remains under wrap include results
from a phase III study of
Johnson & Johnson's(JNJ_) Zytiga in "pre-chemo" prostate cancer patients; a phase III study of
Bayer and Onyx's regorafenib in advanced gastrointestinal stromal tumors;
several Roche/Genentech(RHHBY) studies, including Avastin in ovarian cancer and TDM-1 in breast cancer (partnered with
Immunogen(IMGN_)); melanoma data from
GlaxoSmithKline's(GSK_) targeted drug dabrefenib; and a new targeted PD-1 immunotherapy from
Bristol-Myers Squibb(BMY_).
The following pages summarize new and important cancer drug data
released tonight by ASCO from research abstracts for its upcoming annual
meeting.......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.